Analyzer Diagnostic Post
 |
US $17.50
Innovations in cancer diagnostics. : The progress of technology. Opportunities for growth and Outlook. Market in the future.
Major Trends in the market. IVD and imaging are - based modalities such as computed by focusing on the way to the medical people of doctors and patients. Cost - all those wanting more. Treatment and cost.
This report analyzes the latest innovations in cancer diagnosis and identify the most exciting variety of new technologies and trends. From the body and cytology and molecular diagnostics. Pharmacogenomics. It creates important challenges for innovative diagnostics company.
Key Features of this report.
• Image analysis of the latest innovations in cancer diagnosis in the cover. Magnetic Resonance Imaging (MRI), X -, computed tomography (CT), ultrasound. Positron emission tomography (PET), single photon emission computed tomography. (SPECT) and flow cytometry.
• Analysis the latest innovations in molecular level. How to diagnose and analyze the effects of market-Reports include coverage and glow in the breeding situ (FISH)-polymerase chain reaction (PCR), HPV testing, immunoassays and biomarker microarrays and comparative genomic hybridization. (CGH).
• Analysis of the latest innovations in pharmacogenomics. Extensive and important work of family breast cancer, colon cancer and lung cancer. In addition, an overview report of the regulatory environment and intellectual property for Genetic testing. - Based.
• greater challenge for the entire trade. Innovative diagnostics company, including the impact of the recession. Pay, regulatory Changes and the relationship between the pharmaceutical industry. Academics and
Reports include detailed case study of the potential technologies available in the main area of termination must be found, such as ovarian and colon cancer.
The main advantages of this report.
• Understanding the latest innovations in the market for cancer diagnostics in the area. core - molecular diagnostic imaging diagnosis. and pharmacogenetics, including marketing information and analysis of the scientific literature to identify what is really innovative.
• determine what the most important areas of need. unmet in the market for Products and cancer understand the greatest potential for the next decade.
• Understand the main challenge for cancer. And what is the best strategy to overcome these obstacles.
• Understand the competitive landscape and what the company is a leader in the innovation and the latest craze. Partner judgmental friend
• Depth of the business. 5 The key innovation in the market help for diagnostic strategies. Company Guide
The main Results from this report.
Molecular diagnostics and biomarkers, the most important drivers of the cancer diagnostics market.
Despite the deep economic recession. R & D has held for the company. Diagnosis of cancer, but M & events have affected the value of the deal per year. 2009 lower than in the largest Part of 2007.
The collaboration between the company and society. Drugs and diagnostics are the future of the industry. Sahai offers are in the past year increased.
Virtual Colonoscopy - CT scans used to create an image of the colon. - Is always an acceptable alternative. invasive colonoscopy for colon examination in risk groups and the general public. This offers enormous market opportunities.
Interesting research is being carried out in ovarian cancer and for cancer that broad definition of may have market. The company is committed to review. new biomarkers to create a detailed audit.
A crucial question in this report.
Opening up new markets for what in-vitro diagnostic products?
Market forecasts for the diagnosis of cancer is what
What are the main innovations give in diagnosis and diagnostic?
Important area of need. unfulfilled in cancer diagnostics?
What are the most likely areas of technology and the Diagnosis of cancer. These companies are to use.
What is important is the trend. Impact on the market in the long term?
This can take full advantage of opportunities in the pharmaceutical sector major cancer diagnostics?
Abbott Diagnostics.
Affymetrix.
Beckman Coulter.
Beckton Dickinson.
Bio - Rad
Gen - Probe.
Johnson &. Johnson.
Luminex.
Nanogen.
Roche Diagnostics.
Siemens.
Sysmex.
Content.
Innovations in cancer diagnosis.
10 Executive Summary.
10 Vertical
Innovations in imaging. 11th
Innovations in molecular diagnostics. 12th
Innovations 13 in pharmacogenomics.
The challenge in diagnosing cancer sector. 14th
15 Landscape Competition
Chapter 18 Scene 1
Abstract 18th
Introduction 19th
Cancer Facts. Current and planned 19th
History 23 The diagnosis of cancer.
Elements of cancer diagnosis. 26th
27 Pathology
Cancer diagnosis. 28 Market
Chapter 2: Innovation in imaging. 34th
Abstract 34th
Introduction 35th
Body Image 35th
Overview 35th
X -. 38th ray
38 breast cancer.
40 Calculated Bay.
40 lung cancer.
Cancer. 40th
42 more
Ultrasound-44.
Magnetic resonance imaging 44th
Nuclear medicine. - PET and SPECT-45.
Case Study 47th
HYPER 47th Image
47th Cytology.
Overview 47th
Flow 48th
Case Study 49th
CellSearch 49th
Cervical examination 50th
Provisional 52nd
Chapter 3 of 56 innovative molecular diagnostics.
Abstract 56th
Introduction 57th
DNA, genes and chromosomes. 59th
Glow in the breeding situ (FISH) 59
PCR 60 varieties.
Case Study 61st
HPV testing 61st
Immunoassays and 62 biomarkers.
66 case studies.
Ovarian 66th
PSA testing 68th
70 Other areas of research.
Epigenomics 71st
Microarrays 72nd
Comparative genomic hybridization. (CGH) 73
Case Study 74th
Almac 74th
DiaGenic 74th
Overview of clinical applications of molecular diagnostics. 74th
BCR - ABL 74th
LOH 75th
MSI 75th
Chapter 4 Innovation in 78 pharmacogenomics.
Abstract 78th
Introduction 79th
79 family cancer
80 breast cancer.
Colon cancer 81
Melanoma 81st
Case Study 82nd
Challenging IP 82nd
Response to treatment. 83rd
86 types of cytochrome P450.
HER2 Expression 86th
FDA, EMEA and 88th PGX Label
Case Study 89th
TheraScreen: KRAS-89.
BioTheranostics: 89 Breast cancer.
Clarient: 90 breast cancer.
Mark Erlotinib in lung cancer. 90th
91 companion diagnostics.
Chapter. 5 The challenge in diagnosing cancer sector. 94th
Summary 94
Introduction 95th
Compensation in 1997.
Patient Education = Education decision in 1998.
Regulations. 99th
Pharmacy one hundred and first
104 New Market.
The collaboration between drug companies and 105 academic
Research and Development 106th
Combined. 109 acquisitions and
Competitive landscape Chapter 6 112th
Abstract 112th
Introduction 113th
113 Abbot Diagnostics.
Affymetrix 114th
Beckman Coulter 116th
Becton Dickinson 117th
119 Laboratory Bio - Rad
Gen-Probe - 120
Johnson & Johnson (J & J) 121
Ortho Clinical Diagnostics 121st
Luminex 121st
Tm Bioscience. 122nd
Nanogen 122nd
123 Roche Diagnostics.
Siemens 126 health diagnosis.
Sysmex 126th
View the future of cancer diagnostics market. 127th
Science 127th
128 Infrastructure
Innovation adoption 130th
131 Companion diagnostics.
Chapter 7 Appendix 135th
Terminology 135th
138 Index.
Article
Figure 1.1: Web Site of the United States lead a new cancer. 2009 22nd
Figure 1.2: Leading sites of cancer in developing countries. 2007 23rd
Figure 1.3: The data is based oncologist diagnosed before posting. And 27
Figure 1.4: The diagnosis of cancer. Forecast ($ bn) 2007-14 30th
Figure 2.5: Examples of the image. 3D tomosynthesis 39th
Figure 2.6: Number of CT scans in the United States. 1995-2008 43rd
Figure 2.7: women with mammograms (%) in the United States. 2004 * 45th
Figure 2.8: Flow cytometry expected global market. ($ Bn) 2008-14 48th
Figure 3-9: Market Forecast IV diagnosis. ($ Bn), 2007-2014) 58
Figure 3.10: The use of biomarkers 63.
Figure 3.11: Barriers to development. Biomarker-64.
Figure 3.12: U.S. survive five years (%) for ovarian cancer, while 67 diagnosis
Figure 4.13: a lot: Molecular Diagnostics Sales ($ M) 2005-09 83rd
Figure 4.14: Number of biological control of the CDER data available. PGX 85th
Figure 4.15: Herceptin Fees ($) per patient with the Experiment connected. HER2 87th
Figure 5.16: decline in the index, S. & P Global (%) 12 months in December 1996. 2008th
Figure 5.17: IV diagnostic category the danger. 100th
Figure 5.18: FDA review of biomarkers therapy area in September. 2009 102nd
Figure 5.19: Roche Diagnostics Sales Region (million CHF). 2008 105th
Figure 5.20: Adding leading diagnostic R & D use (%) 2008 107th
List of table
Table 1.1: WHO expected cancer mortality Region. (000), 21st 2008-30
Table 1.2: In-vitro diagnostics market expectations. ($ Bn) 2008-14 29th
Table 2.3: Overview of 37 images system.
Table 2.4: Reduction in mortality (%) due to a single. Check FOBT, 1985-1996 41st
Table 2.5: Data-rays. Organ from clinical studies of the various 44th
Table 3.6: Study of the biomarkers. Cancer 65th
Table 3.7: Potential Market For the testing of specific cancer Epigenomics 72nd
Table 4.8: Lack money completely (%) The drug therapy. 84th
Table 5.9: M and agreements necessary for diagnosis. Industry ($ m), 2009 109th
Table 6.10. : Sales for leading innovative diagnostics. ($ M), 113 2006-08 cancer
Table 6.11: Beckman Coulter R & D investment ($ M), 116 2004-08.
Table 6.12: Bio - Rad sales (billion $) 2004-2008 119th
Table 6.13: Roche Diagnostics sales (million CHF), H109 divided 123rd
Table 6.14. : Major Last 132 DX - Rx partners.
For further information please contact
About the Author
Minal H
SEO
vinod.minal@gmail.com
http://www.aarkstore.com
Preventing Adverse Health Effects from Nanotechnology
Pharmaceutical, Healthcare & Life Sciences
21 Sep 2010 - United States - Pharmaceutical, Healthcare & Life Sciences - Life Sciences Newsbriefs: Week of September 20, 2010 - McGuireWoods LLP - Sen. Al Franken, D-Minn., urged FDA Commissioner Margaret Hamburg to consider the concerns of the medical-device sector in Minnesota and elsewhere and gather further public comments as the agency works to introduce changes to the 510(k) process for ...
No comments yet.
Leave a comment